Xenon Pharmaceuticals
XENE
130 hedge funds and large institutions have $1.44B invested in Xenon Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 50 increasing their positions, 27 reducing their positions, and 24 closing their positions.
176% more capital invested
Capital invested by funds: $521M → $1.44B (+$916M)
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
85% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 27
58% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 24
31% more call options, than puts
Call options by funds: $6.15M | Put options by funds: $4.71M
10% more funds holding
Funds holding: 118 → 130 (+12)
9.51% more ownership
Funds ownership: 82.93% → 92.44% (+9.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$57.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$51.3M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$50.4M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$48.2M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$42.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$20.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.2M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$15.2M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$14M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$7.68M |
XENE Hedge Fund Activity: Q4 2021 in Review
130 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2021, worth a combined $1.44B — up 176% from $521M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new XENE positions and 24 closed out — a net gain of 14 holders — while 50 added to existing stakes and 27 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $57.2M. The largest seller was Ghost Tree Capital, cutting an estimated $20.6M.
- 130 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2021, up from 118 in Q3 2021.
- Funds reported $1.44B of Xenon Pharmaceuticals stock for Q4 2021, up 176% quarter-over-quarter.
- 38 funds opened new Xenon Pharmaceuticals positions in Q4 2021 and 24 closed out, a net change of +14 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2021 was Point72 Asset Management, an estimated $57.2M added.
- The largest Xenon Pharmaceuticals seller in Q4 2021 was Ghost Tree Capital, an estimated $20.6M sold.
Based on aggregated 13F filings for Q4 2021.